Figure 3.

Orelabrutinib preserved rituximab-mediated cytotoxicity

(A) NK cells pretreated with 1 μmol/L BTK inhibitor, ibrutinib, or Orel were co-cultured with B lymphoma cells at different E:T ratio in the presence of rituximab (RTX) at a concentration of 10 μg/mL or not. (B) Pretreated NK cells with 1 μmol/L ibrutinib or Orel were co-cultured with B lymphoma cells at 5:1 in the presence of 10 μg/mL rituximab or PBS. (C) Rituximab (10 μg/mL) or PBS was combined with the increasing concentration of Orel to evaluate tumor cell lysis induced by NK-cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Cell supernatant was collected after 4-h co-culture and then was measured for lactate dehydrogenase (LDH) with Non-Radioactive Cytotoxicity Assay. Each cell line was biologically tested for at least 3 times. ∗p < 0.05 and ∗∗p < 0.01 compared with control group.